Sino Biopharmaceutical Limited board of directors announced that "Decitabine for injection" (product name: Qingweike (specifications: 10mg, 25mg and 50mg), an anti-hematological tumor drug developed by the Group, has obtained the notice of approval of supplemental application on pharmaceutical product issued by the National Medical Products Administration of the People's Republic of China, and passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs ("Consistency Evaluation"). Decitabine is a specific inhibitor of deoxyribonucleic acid (DNA) methylation. It inhibits DNA methyltransferase through incorporation into DNA, causing DNA hypomethylation and cell differentiation or apoptosis to exert anti-tumor effects. Decitabine has shown high efficacy in the treatment of high-risk myelodysplastic syndrome (MDS), refractory and recurrent acute myeloid leukemia (AML) and chronic myelogenous leukemia (CML). The production and sales volume of Decitabine for injection developed by the Group has been increasing year by year since its launch in 2012. Passing the Consistency Evaluation, Decitabine for injection of the Group is recognized as an alternative to the imported pharmaceutical preparation, providing clinicians and patients with another solid choice for the treatment of MDS.